Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Income from Continuing Operations (2016 - 2025)

International Stem Cell (ISCO) has disclosed Income from Continuing Operations for 16 consecutive years, with 91000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Income from Continuing Operations fell 20.18% to 91000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was 240000.0, a 65.17% increase, with the full-year FY2024 number at 213000.0, up 73.44% from a year prior.
  • Income from Continuing Operations was 91000.0 for Q2 2025 at International Stem Cell, up from 218000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 114000.0 in Q2 2024 to a low of 641000.0 in Q3 2021.
  • A 5-year average of 194833.33 and a median of 155000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 8850.0% in 2023, then surged 163.69% in 2024.
  • International Stem Cell's Income from Continuing Operations stood at 362000.0 in 2021, then soared by 107.73% to 28000.0 in 2022, then tumbled by 1735.71% to 458000.0 in 2023, then skyrocketed by 102.62% to 12000.0 in 2024, then skyrocketed by 658.33% to 91000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Income from Continuing Operations are 91000.0 (Q2 2025), 218000.0 (Q1 2025), and 12000.0 (Q4 2024).